BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33218184)

  • 21. In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus.
    Pan Y; Zhang J; Zhou L; Zuo J; Zeng Y
    Biochem Biophys Res Commun; 2006 Sep; 347(3):551-7. PubMed ID: 16842756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Quantitative and localized detection of Epstein-Barr virus infectious status in nasopharyngeal carcinoma tissue].
    Jiang WH; Zhao SP; Yin ZH; Li F; Chen ZH; Xiao JY
    Ai Zheng; 2005 Jul; 24(7):796-800. PubMed ID: 16004803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
    Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
    J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
    Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy.
    Liu WN; Fong SY; Tan WWS; Tan SY; Liu M; Cheng JY; Lim S; Suteja L; Huang EK; Chan JKY; Iyer NG; Yeong JPS; Lim DW; Chen Q
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dermal CD207-Negative Migratory Dendritic Cells Are Fully Competent to Prime Protective, Skin Homing Cytotoxic T-Lymphocyte Responses.
    Hain T; Melchior F; Kamenjarin N; Muth S; Weslati H; Clausen BE; Mahnke K; Silva-Vilches C; Schütze K; Sohl J; Radsak MP; Bündgen G; Bopp T; Danckwardt S; Schild H; Probst HC
    J Invest Dermatol; 2019 Feb; 139(2):422-429. PubMed ID: 30296420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus infection in precursor lesions of nasopharyngeal carcinoma.
    Zhong BL; Zong YS; Lin SX; Zhang M; Liang YJ
    Ai Zheng; 2006 Feb; 25(2):136-42. PubMed ID: 16480574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presence of lytic Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Yu F; Lu Y; Petersson F; Wang DY; Loh KS
    Head Neck; 2018 Jul; 40(7):1515-1523. PubMed ID: 29522272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
    Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
    Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spatiotemporal homogeneity and distinctness of the T-cell receptor β-chain repertoires in Epstein-Barr virus-associated primary and metastatic nasopharyngeal carcinomas.
    Chung YL; Wu ML
    Int J Cancer; 2018 Aug; 143(3):610-620. PubMed ID: 29468660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.
    Ramayanti O; Verkuijlen SAWM; Novianti P; Scheepbouwer C; Misovic B; Koppers-Lalic D; van Weering J; Beckers L; Adham M; Martorelli D; Middeldorp JM; Pegtel DM
    Int J Cancer; 2019 May; 144(10):2555-2566. PubMed ID: 30411781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.
    Khanna R; Busson P; Burrows SR; Raffoux C; Moss DJ; Nicholls JM; Cooper L
    Cancer Res; 1998 Jan; 58(2):310-4. PubMed ID: 9443410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr virus infection and nasopharyngeal carcinoma.
    Tsao SW; Tsang CM; Lo KW
    Philos Trans R Soc Lond B Biol Sci; 2017 Oct; 372(1732):. PubMed ID: 28893937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of transcripts initiated from two viral promoters (Cp and Wp) in Epstein-Barr virus-infected nasopharyngeal carcinoma cells and biopsies.
    Chang Y; Sheen TS; Lu J; Huang YT; Chen JY; Yang CS; Tsai CH
    Lab Invest; 1998 Jun; 78(6):715-26. PubMed ID: 9645762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in cancer gene copy number alterations between Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma.
    Ooft ML; van Ipenburg J; van de Loo RJM; de Jong R; Moelans CB; de Bree R; de Herdt MJ; Koljenović S; Baatenburg de Jong R; Hardillo J; Willems SM
    Head Neck; 2018 Sep; 40(9):1986-1998. PubMed ID: 29927011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma.
    Zhang XS; Wang HH; Hu LF; Li A; Zhang RH; Mai HQ; Xia JC; Chen LZ; Zeng YX
    Cancer Lett; 2004 Jul; 211(1):11-8. PubMed ID: 15194212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
    Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
    Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.